Polypeptide for the treatment of cancer and a method for preparation thereof
US6720311B2 · kind B2 · utility
Inventor
Key dates
| Filing date | May 14, 2002 |
| Grant date | Apr 13, 2004 |
| Priority date | — |
| Expiry date | May 15, 2022 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07K14/71
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
This invention characterizes the specific peptide fragment derived from specially prepared zinc charged fetuin and a method of preparation thereof, wherein the fragment was found to contain an apoptosis-inducing activity. Specifically, the amino acid sequence of this peptide is H-T-F-S-G-V-A-S-V-E and correlates to amino acid no. 300-309 of fetuin, referred to herein as Fetuin Peptide Fragment (FPF 300-09). FPF 300-09 strongly induced apoptosis in LNCaP (prostate cancer) and HT-29 (colon cancer) cells without affecting CCD 18 Co (normal colon) cells. The in vitro tissue culture study demonstrated that the FPF 300-09 is more potent than the parent molecule (full-length zinc charged fetuin) in inducing apoptosis. FPF 300-09 has a LD50 of 0.3-0.4 &mgr;M, while the LD50 for zinc-charged fetuin is 3-10 &mgr;M.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.